Concrete mix design and aggregate tests data between 2009 and 2017 in Sudan.

Over 1000 mix designs data and more than 1400 fine and coarse aggregates tests results data were collected for the previous 10 years in Sudan. The data was organized into spreadsheets creating a data base useful for future studies. The data includes mix designs proportions in terms of cement content, water, fine and coarse aggregate in addition to the used admixtures.

Causes of suboptimal corrected visual acuity following phacoemulsification in a teaching university hospital.

Purpose: Cataract is the leading cause of reversible blindness in developing countries, with variable visual outcome following surgery. This work aims at assessing the outcomes of cataract surgery at Kasr Al Ainy Hospital and identifying the reasons for borderline and poor outcome in the studied group.

Methods: A total of 150 eyes of patients with cataract and no other ocular pathology were included in this study.

Serial serum alkaline phosphatase as an early biomarker for osteopenia of prematurity.

Metabolic bone disease of prematurity is a condition characterized by reduction in bone mineral content (osteopenia). It is a problem faced by very low birth weight (VLBW) infants because of lack of fetal mineralization during the last trimester. Our aim was to assess serum alkaline phosphatase (ALP) level as an early biomarker for osteopenia in premature infants and to estimate an optimal cutoff value of serum ALP at which osteopenia is detected radiologically in premature newborns.

Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.

Background: In many European jurisdictions, relative effectiveness assessments (REAs) of pharmaceuticals are performed during the reimbursement decision-making process. International collaboration in the production of these assessments may prevent the duplication of information in various jurisdictions. A first pilot of a joint REA (pazopanib for the treatment of renal cell carcinoma) was published in 2011.